Solara Active Pharma Sciences Allots 1,500 Equity Shares Under ESOP Plan

Solara Active Pharma Sciences Limited , a prominent player in the pharmaceutical industry, continues to strengthen its employee incentive programs through strategic stock option allotments. The company's Board of Directors recently approved another allotment under the Solara Employee Stock Option Plan 2018.

Latest ESOP Allotment Details

On December 17, 2025, the Board of Directors approved the allotment of 1,500 equity shares under the employee stock option plan. The key details of this latest allotment are:

Parameter:	Details
Number of Shares Allotted:	1,500 equity shares
Face Value:	Rs. 10.00 each
Exercise Price:	Rs. 375.00 per share
Funds Raised:	Rs. 5.63 lakhs
Allotment Date:	December 17, 2025

Updated Share Capital Structure

The allotment has resulted in changes to the company's share capital structure:

Share Capital Component:	Before Allotment	After Allotment
Equity Shares - Fully Paid:	3,61,71,307	3,61,72,807
Total Paid-up Capital:	Rs. 44,48,74,123.50	Rs. 44,48,89,123.50
Total Shares Outstanding:	4,81,70,062	4,81,71,562

The newly allotted shares rank pari-passu with existing equity shares in all respects.

Previous ESOP Activities

This follows the company's earlier allotment of 8,040 equity shares in November 2025, which raised Rs. 30.15 lakhs. The company had also previously granted 25,000 stock options to employees with an exercise price of Rs. 375.00 per share and a structured vesting schedule over three years.

Financial Performance Context

The diluted earnings per share remains at Rs. 19.00 following this allotment. These employee stock option exercises are part of Solara's broader strategy to align employee interests with shareholder value while the company works on improving its financial performance and exploring strategic restructuring opportunities including the potential demerger of its CRAMS and Polymers business.

Regulatory Compliance

The allotment complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options were exercised within the prescribed 120-day period from the vesting date.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.03%	-4.87%	+6.57%	+1.51%	-15.44%	-49.29%

Solara Active Pharma Sciences Limited , a prominent player in the Active Pharmaceutical Ingredient (API) sector, has announced significant changes to its board composition, senior management team, and key appointments.

Board Reshuffle and Committee Reconstitution

The company reported that Mr. Kartheek Chintalapati Raju has stepped down from his position as Non-Executive Director, citing preoccupation and personal commitments. Consequently, he has also relinquished his roles in the Stakeholders Relationship Committee and Nomination and Remuneration Committee.

In response to these changes, Solara Active Pharma Sciences has reconstituted its board committees:

Stakeholders Relationship Committee:

Role	Name
Chairperson	Dr. Kausalya Santhanam (Independent Director)
Member	Mr. Sandeep Shashikantha Rao (Executive Director)
Member	Mr. Manish Gupta (Non-Executive Director)

Nomination and Remuneration Committee:

Role	Name
Chairperson	Mr. Rajendra Kumar Srivastava (Independent Director)
Member	Dr. Kausalya Santhanam (Independent Director)
Member	Mr. R Ramakrishnan (Independent Director)
Member	Mr. Rajiv Vijay Nabar (Independent Director)

The company expressed its appreciation for Mr. Raju's contributions during his tenure.

New Chief Human Resources Officer Appointed

Solara Active Pharma Sciences has appointed Mr. Mohanraj S as the new Chief Human Resources Officer (CHRO) and designated him as Senior Management Personnel. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.

Mr. Mohanraj brings over 30 years of cross-industry experience to the role, with expertise spanning Pharma, Biotech, Engineering, Aerospace, Apparel, and Media sectors. His career includes leadership positions at Mylan Laboratories, The Manipal Group, and Tata Advanced Materials. His areas of expertise encompass Talent Management, Employee Relations, Organizational Development, HRIS, and Digital Transformation.

Mr. Mohanraj holds a Masters in Social Work (HRM) from Madras University and a BA in Behavioural Sciences from St. Josephs College, Bangalore. He is also a certified ISO auditor and has served on the Board of Studies for Industrial Relations at St. Josephs University for two decades.

As Solara's HR head, Mr. Mohanraj will be responsible for leading people strategy, culture transformation, and governance to align HR with the company's long-term business goals.

Additional Management Changes and Remuneration Revisions

The Board of Directors has made several other key decisions:

Mr. Sarat Kumar Asuri, the current Chief Financial Officer, has been appointed to the additional role of Chief Investor Relations Officer.
The Board approved a revision in remuneration for Whole-time Director Mohan Muthunarayanan. This revision is within the previously approved shareholder limits and aligns with the company's remuneration policy guidelines.
Remuneration for eligible Senior Management Personnel has been revised.
The company's existing Risk Management Policy was reviewed and confirmed.

These changes reflect Solara Active Pharma Sciences' commitment to strengthening its leadership structure and aligning management incentives with company performance and shareholder interests.